Drug intelligence / Profile preview

Sindbis virus wild-type

Development stage: Preclinical
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Subcutaneous, Intracranial, Intraperitoneal, Intravenous, Dermal

Overview

Sindbis virus wild-type (SINV-WT) is a naturally occurring alphavirus being investigated for its oncolytic properties. It has demonstrated the ability to effectively infect hepatocellular carcinoma cell lines and induce cell death, indicating its potential as a therapeutic agent for liver cancer. This wild-type virus serves as the foundational platform for engineered variants, such as SINV-GM-CSF, which incorporate additional therapeutic elements.

Other names: Sindbis virus

Targets

RPSA (37/67 kDa laminin receptor)

Beyond the preview

Go deeper on Sindbis virus wild-type.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sindbis virus wild-type.

Explore the full profile